A carregar...
Monitoring Afatinib Treatment in HER2-Positive Gastric Cancer with (18)F-FDG and (89)Zr-Trastuzumab PET
We evaluated the ability of the PET imaging agent (89)Zr-trastuzumab to delineate HER2-positive gastric cancer and to monitor the pharmacodynamic effects of the epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitor afatinib. METHODS: Using...
Na minha lista:
| Publicado no: | J Nucl Med |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4967936/ https://ncbi.nlm.nih.gov/pubmed/23578997 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.112.110239 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|